- Home
- DXR
as 04-23-2025 3:35pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 40.3M | IPO Year: | N/A |
| Target Price: | $25.00 | AVG Volume (30 days): | 5.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | 86.16 |
| 52 Week Low/High: | $6.55 - $10.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $119,714 | Revenue Growth: | -26.75% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Daxor Corporation (DXR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Feldschuh Michael Richard | DXR | Chief Executive Officer | Apr 4 '25 | Buy | $7.89 | 2,063 | $16,277.07 | 212,694 | |
| Feldschuh Michael Richard | DXR | Chief Executive Office | Mar 26 '25 | Buy | $8.13 | 1,000 | $8,130.00 | 212,694 | |
| Feldschuh Michael Richard | DXR | Chief Executive Officer | Mar 19 '25 | Buy | $8.15 | 647 | $5,273.05 | 212,694 | |
| Michel Robert J | DXR | Chief Financial Officer | Mar 10 '25 | Buy | $8.00 | 1,000 | $8,000.00 | 17,050 | |
| Feldschuh Michael Richard | DXR | Chief Executive Officer | Mar 10 '25 | Buy | $7.70 | 4,852 | $37,323.04 | 212,694 |
Latest Daxor Corporation News
DXR Breaking Stock News: Dive into DXR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Daxor Corporation to Exhibit at the 45th International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions
GlobeNewswire
7 days ago
Daxor Corporation to Showcase Innovative Blood Volume Analysis at MedAxiom Cardiovascular Transforum Spring 2025
GlobeNewswire
9 days ago
New Research at ACC25 Shows Daxor BVA-Identified Euvolemic Heart Failure Patients Experience 2.61 Times Better Survival
GlobeNewswire
14 days ago
Daxor Corporation Submits 510(k) to FDA for Next-Generation Blood Volume Analyzer
GlobeNewswire
22 days ago
Daxor Corporation Announces New Data from Duke University and Highlights Key BVA Insights at American College of Cardiology’s 74th Annual Scientific Session and Expo
GlobeNewswire
a month ago
Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks
GlobeNewswire
2 months ago
Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024
GlobeNewswire
2 months ago
Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025
Compare DXR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.